on Pentixapharm Holding AG (isin : DE000A40AEG0)
Pentixapharm Signs Manufacturing Deal for Yttrium-90 Therapy
Pentixapharm Holding AG has inked a manufacturing agreement with Eckert & Ziegler Radiopharma GmbH, a subsidiary of Eckert & Ziegler SE. As per the agreement, Eckert & Ziegler will produce and supply patient-specific doses of Y90-PentixaTher, Pentixapharm's primary radiotherapeutic agent targeting CXCR4 receptors, for clinical trials.
Y90-PentixaTher focuses on cancer cells exhibiting an abundance of CXCR4 receptors, a marker found in several malignancies including leukemias and solid tumors. This compound uses Yttrium-90, ensuring deeper tissue penetration and effective radiation therapy. Notably, this agreement is confined to the clinical development phase, allowing Pentixapharm strategic flexibility for future scale-up decisions.
The collaboration marks a significant progression in Pentixapharm’s oncology program, supporting advancements in targeted cancer therapies. Industry stakeholders emphasize the critical role of accessible radioisotopes in developing novel radiopharmaceuticals.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Pentixapharm Holding AG news